Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype - ACOSOG Z1031
Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Li Lin, Jacqueline Snider, Aleix Prat, Joel S. Parker, Jingqin Luo, Katherine DeSchryver, D. Craig Allred, Laura J. Esserman, Gary W. Unzeitig, Julie Margenthaler, Gildy V. Babiera, P. Kelly Marcom, Joseph M. Guenther, Mark A. Watson, Marilyn Leitch, Kelly Hunt, John A. Olson
Dive into the research topics of 'Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype - ACOSOG Z1031'. Together they form a unique fingerprint.